The Journal of Clinical Endocrinology and MetabolismNov 3, 2026, 03:24 GMT

Diabetes drug class not clearly linked to thyroid cancer worsening

Drug users had a hazard ratio—a measure of relative risk over time—of 0.87 for cancer recurrence or progression versus never-exposed patients, with uncertainty including no difference.

Paper by Armando Patrizio, Audrey Mauguen, James A. Fagin, +7Laura Boucai · University of Pisa · Memorial Sloan Kettering Cancer Center

Our read

Interventions

Studied:: Cohort study of 840 adults with differentiated thyroid cancer, median 69 months
What changed:: Thyroid cancer recurrence or worsening did not clearly differ between drug users and never-users (hazard ratio 0.87)
The catch:: Median drug exposure was only 16 months, limiting assessment of longer-term cancer progression
In the record:: The 877th paper on GLP-1 receptor agonists with results in people; 4,947 on record in all.

Editor of record: Boris Djordjevic · AgingResearch.News

Paper

A retrospective observational cohort study compared 536 adults with differentiated thyroid cancer, which arises from thyroid hormone-producing cells, with 536 matched patients. The first group used glucagon-like peptide-1 receptor agonists or related dual-action drugs for diabetes or obesity; the comparison group had never used these drugs. These included semaglutide and tirzepatide. Patients’ median age was 49; 71% were female and 54% had diabetes.

Median drug exposure was 16 months, and median follow-up was 69 months. In an analysis of 840 patients, drug use was not significantly associated with cancer recurrence or progression after adjustment for other risk factors. The range of likely values included no difference. The full cohort analysis also found no significant association. During follow-up, 14 drug users and 13 comparison patients died. The authors concluded that eligible patients should not be denied these drugs’ heart and metabolic benefits when clinically indicated.

Why it matters

For adults aging with thyroid cancer and diabetes or obesity, the study addresses whether managing metabolic health is linked to cancer returning or worsening.

Caveats

This single-center observational study cannot establish cause and effect or show that the drugs are risk-free. The results do not cover medullary thyroid cancer or unresected low-risk thyroid cancers managed with surveillance, which were excluded.